An experimental treatment, gantenerumab, failed to help people at high risk of memory loss from Alzheimer’s or those who were in the early phases of the disease, the manufacturer said Monday.
Related Posts
10 doctors on FDA panel for Abbott heart device had financial ties to the company
When a group of FDA advisors recently assessed a h
White House press secretary Jen Psaki tests positive (again) for COVID-19
In a statement posted to Twitter, Psaki says s
Fake Botox is the cause of bad reactions in 9 states, FDA says
Fake Botox is behind 19 reports of vision problems